Xtant Medical Holdings, Inc. (NYSE American:XTNT) reported third-quarter 2026 financial results on November 16, 2026, disclosing a net loss of $3.6 million, year-over-year revenue declines, and the withdrawal of its full-year 2026 financial guidance amid an ongoing Board-led strategic review.
Key Highlights
- Total revenue: $24.3 million for Q3 2026, down from $33.3 million in Q3 2025 and up 5% from $23.0 million in Q2 2026.
- Biologics revenue: $19.3 million, up 13% from $17.1 million in Q3 2025 and up 11% from $17.4 million in Q2 2026, including $2.2 million from HEMOBLAST Bellows sales.
- Net loss: $3.6 million, or $0.03 per share, compared to net income of $1.3 million, or $0.01 per diluted share, in Q3 2025.
- Adjusted EBITDA: A loss of $1.5 million for Q3 2026, compared to adjusted EBITDA of $4.5 million for Q3 2025.
- Gross margin: 56.3% in Q3 2026, compared to 66.1% in Q3 2025.
- Guidance withdrawn: The company disclosed it no longer expects to achieve its previously issued full-year 2026 guidance and is not providing revised guidance.
- Liquidity: $7.8 million in cash and cash equivalents as of September 30, 2026, with $2.1 million of revolving credit availability.
Xtant Medical Reports Revenue Decline and Strategic Review Progress in Q3 2026
According to the filing, total revenue for the third quarter of 2026 was $24.3 million, down from $33.3 million in the same period of 2025. The company attributed the year-over-year decline primarily to the absence of $5.4 million of prior-year revenue from divested non-core Coflex/CoFix assets and an international hardware business, and the absence of $5.5 million of prior-year wound care licensing revenue, partially offset by $2.2 million of HEMOBLAST revenue. Sequentially, revenue was up 5% from $23.0 million in Q2 2026.
Gross margin declined to 56.3% from 66.1% in Q3 2025, with the filing noting a 670-basis-point impact from the cessation of high-margin wound care licensing revenue and a 360-basis-point impact from sales mix. Operating expenses decreased to $16.7 million from $19.5 million, as general and administrative expenses fell to $5.0 million from $7.1 million and sales and marketing expenses decreased to $11.2 million from $11.7 million. The company reported a net loss of $3.6 million, or $0.03 per share, reversing net income of $1.3 million, or $0.01 per diluted share, in Q3 2025.
As of September 30, 2026, the company reported $7.8 million in cash and cash equivalents, total indebtedness of $22 million (consisting of $10.2 million of current and long-term debt and $11.8 million in revolving credit borrowings), and $2.1 million of revolving credit availability. The filing stated that, "based on its current operating plan, the Company expects its cash and cash equivalents, and availability under its revolving credit facility, to be sufficient to fund operations for at least the next 12 months." The Board disclosed it is conducting a strategic review evaluating a broad range of potential actions, including operational improvements, capital structure alternatives, partnerships, restructurings, acquisitions, and dispositions, with no timetable set for completion. The company stated it will not host a conference call to discuss Q3 2026 results.
What Was Disclosed
Xtant Medical filed its Q3 2026 earnings release disclosing a net loss, year-over-year revenue declines driven by prior divestitures and the loss of wound care licensing revenue, withdrawal of full-year 2026 guidance, and an active Board-led strategic review with no defined timeline.



Please wait processing your request...